Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)
← catalyst calendarNCT07502599 · readout ≤ 772 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
40estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-06 | actual | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Orthostatic Hypotension
- Reflex Syncope
Interventions
- Device: Wearable holter monitor
- Device: Wearable holter monitor
Primary outcome
what the primary-completion date above is the date OFPhysiologic Signal Detection via wearable holter monitor
measured From enrollment through the 21 day follow up period
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed